Biologic Adjuvants for the Management of Osteochondral Lesions of the Talus

MaCalus V. Hogan, MD, MBA; Justin J. Hicks, MD; Monique C. Chambers, MD, MSL; John G. Kennedy, MD, FRCS


J Am Acad Orthop Surg. 2019;27(3):e105-e111. 

In This Article


The optimal management of OLT is still undefined. An international consensus meeting on the treatment of OLTs was recently held at the University of Pittsburgh (M.V.H.).[35] The results of this meeting as it pertains to biologics were reported.[36] Concerns regarding the biologic shortcomings of current reparative and replacement strategies still remain. Biologic adjuncts using stem cells, growth factors, HA, scaffolds, or a combination thereof are potential interventions that may enhance the regeneration of these defects. In vitro and preclinical animal models support this hypothesis, and early clinical studies of biologic augmentation are promising. Research exploring the efficacy of these biologic treatment modalities is underway and may improve the outcomes of OLT treatment in the future.